April 3 (Reuters) - Pardes Biosciences Inc said on Monday it will suspend further clinical development of its experimental drug pomotrelvir, after it did not meet the main goal of a mid-stage trial for treating COVID-19. (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri)
Pardes Biosciences, Inc.
Equities
PRDS
US69945Q1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |